TY - JOUR
T1 - Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer
AU - Raynaud, Christophe M.
AU - Mercier, Olaf
AU - Dartevelle, Philippe
AU - Commo, Frédéric
AU - Olaussen, Ken André
AU - De Montpreville, Vincent
AU - André, Fabrice
AU - Sabatier, Laure
AU - Soria, Jean Charles
N1 - Funding Information:
The work in the Laure Sabatier laboratory was supported by TELINCA (Telomere Research Program of the Institut National du Cancer) and RISC-RAD (Radiosensitivity of Individuals and Susceptibility to Cancer Induced by Ionizing Radiations; contract number FI6R-CT2003-508842). We thank Dr. Fabrizio D’Adda di Fagagna for his interactions and helpful discussions. Christophe Raynaud is a doctoral fellow funded by a CEA (Commissariat à l'Energie Atomique)-Lilly Fellowship.
PY - 2010/1/1
Y1 - 2010/1/1
N2 - Background: Recent studies suggest that chemokines are involved in organ-specific metastatic relapse. We evaluated the potential implications of chemokine receptors in the development of adrenal metastasis after complete resections of primary non-small-cell lung cancer. Patients and Methods: We studied a unique cohort of 21 primary lung cancers with matched adrenal metastases for the expression of CX3CR1, CXCR4, CCR6, and CCR7, using immunohistochemistry. Results: Although CXCR4, CX3CR1, and CCR7 were independently expressed in primary and corresponding metastases, CCR6 was clearly overexpressed in adrenal metastases, compared with corresponding primary tumors. Moreover, CCL20, the ligand of CCR6, was preferentially expressed in adrenal tissues that developed metastases. Conclusion: We report for the first time (to the best of our knowledge) a potential role for the CCR6 receptor in the organ orientation of the development of metastases in lung cancer. We demonstrated a statistically significant overexpression of CCR6 in adrenal metastases compared with primary lung tumors, indicating that the increased production of CCL20 in adrenal glands might contribute to the selective recruitment of CCR6-expressing cancer cells in lung cancer. This study, in concordance with the data obtained in animal models, suggests that the chemokine receptor family constitutes a biologic support of the "seed and soil" theory.
AB - Background: Recent studies suggest that chemokines are involved in organ-specific metastatic relapse. We evaluated the potential implications of chemokine receptors in the development of adrenal metastasis after complete resections of primary non-small-cell lung cancer. Patients and Methods: We studied a unique cohort of 21 primary lung cancers with matched adrenal metastases for the expression of CX3CR1, CXCR4, CCR6, and CCR7, using immunohistochemistry. Results: Although CXCR4, CX3CR1, and CCR7 were independently expressed in primary and corresponding metastases, CCR6 was clearly overexpressed in adrenal metastases, compared with corresponding primary tumors. Moreover, CCL20, the ligand of CCR6, was preferentially expressed in adrenal tissues that developed metastases. Conclusion: We report for the first time (to the best of our knowledge) a potential role for the CCR6 receptor in the organ orientation of the development of metastases in lung cancer. We demonstrated a statistically significant overexpression of CCR6 in adrenal metastases compared with primary lung tumors, indicating that the increased production of CCL20 in adrenal glands might contribute to the selective recruitment of CCR6-expressing cancer cells in lung cancer. This study, in concordance with the data obtained in animal models, suggests that the chemokine receptor family constitutes a biologic support of the "seed and soil" theory.
KW - Adrenal gland homing
KW - Adrenal metastases
KW - CCL20
KW - Lymphatic vessel invasion
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=77952501648&partnerID=8YFLogxK
U2 - 10.3816/CLC.2010.n.024
DO - 10.3816/CLC.2010.n.024
M3 - Article
AN - SCOPUS:77952501648
SN - 1525-7304
VL - 11
SP - 187
EP - 191
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 3
ER -